Approach
Bicycles address therapeutic needs unreachable with any other existing modality.

Approach

Bicycles address therapeutic needs unreachable with any other existing modality.

An entirely new class of therapies

Based on groundbreaking work conceived in the laboratory of Sir Greg Winter and Professor Christian Heinis, we are pioneering the development of bicyclic peptides, or Bicycles® — a new class of versatile, chemically synthesised medicines. Bicycles address therapeutic needs unreachable with any other existing modality. Their small size and exquisite tumour targeting delivers rapid tumour penetration and retention while clearance rates and routes can be tuned to minimise exposure of healthy tissue and toxicities.

Key properties of Bicycles

A flexible, modular platform

Bicycles are highly flexible, allowing rapid molecular assembly into more complex molecules.

Bicycles can be used to generate more complex molecules

Bicycle Toxin Conjugates

Our Bicycle Toxin Conjugates are tripartite molecules using a Bicycle to recognise and bind to a tumour-expressed target, a tumour microenvironment cleavable linker and a cytotoxin payload. The linker and coupling chemistry hold the payload inert until the conjugate is localised in the tumour microenvironment. This targeted approach rapidly delivers payloads into solid tumours, with extensive tissue penetration, a short duration of systemic exposure and liver-sparing rapid renal elimination. These properties limit the body’s exposure to toxin to control any damage to normal tissue.

Learn more about our Bicycle Toxin Conjugates, including our lead molecule, BT1718.

A unique screening platform

Our unique optimised platform combines biology with chemistry – we utilise synthetic biology to display an unimaginable diversity (quadrillions) of linear peptides on the surface of engineered bacteriophages and chemistry to transform them into Bicycles. We can rapidly select those that bind to a chosen biological target and use evolution-driven, informed selection to drive hit to lead and rapidly derive optimum molecules.

Our screening platform can be deployed to screen either soluble proteins or cell-based targets. The process is resource efficient and rapid and, uniquely, uses an integral on-phage binding assay which informs structure activity relationships. We can incorporate a diverse range of small molecule scaffolds into Bicycles to increase diversity and confer differentiated physicochemical and structural properties.

We have demonstrated unprecedented success selectively drugging diverse target classes, including cytokines, chemokines, enzymes, proteases and a diverse collection of cell surface receptors (GPCRs, extracellular tethered enzymes and receptor tyrosine kinases).

A breadth of therapeutic opportunities

We are rapidly advancing our robust pipeline of Bicycles for oncology, while pursuing collaborative partnerships with other companies in additional disease areas. This strategy enhances our ability to bring this important class of medicines to patients with debilitating diseases.

Learn more about our oncology pipeline and our activities beyond oncology.